Document:

Exhibit 10.6

 

Term Sheet between

 

MedTech Acquisition
Corporation (the “Issuer”), TriSalus Life Sciences, Inc. (the

 “Target”) and Magnetar Capital LLC, on behalf of one or more affiliates (the

 “Purchaser”)

 

November 11, 2022

 

THIS SUMMARY OF TERMS IS FOR DISCUSSION
PURPOSES ONLY. OTHER THAN THE SECTIONS OF THIS TERM SHEET TITLED “CONFIDENTIALITY”, “EXPENSES”, “GUARANTY”,
 “INDEMNIFICATION”, “EXCLUSIVITY”, “TERMINATION”, “WAIVER AGAINST TRUST ACCOUNT”, AND
 “GOVERNING LAW”, EACH OF WHICH SHALL BE BINDING ON THE PARTIES HERETO. NOTHING HEREIN IS INTENDED TO OR SHALL CONSTITUTE
OR EVIDENCE A BINDING OFFER OR AGREEMENT AMONG THE PARTIES, BUT RATHER FORMS THE GENERAL BASIS FOR DISCUSSIONS RELATING TO SUCH FINANCING
AND THE GENERAL BASIS ON WHICH THE PURCHASER IS PREPARED TO CONTINUE NEGOTIATIONS AND DUE DILIGENCE, AND NO OBLIGATION AMONG THE PARTIES
SHALL ARISE UNLESS AND UNTIL ALL NECESSARY CONSENTS AND APPROVALS HAVE BEEN OBTAINED AND MUTUALLY SATISFACTORY DEFINITIVE WRITTEN AGREEMENTS
HAVE BEEN PREPARED AND EXECUTED.

 

	Issuer:	 	MedTech Acquisition Corporation,
    a Delaware corporation.
	 	 	 
	Securities:	 	Senior secured convertible notes (the “Notes”).
	 	 	 
	Issuance Amount:	 	Up to $50,000,000 total principal amount, not including
    the Greenshoe.
	 	 	 
	Funded Indebtedness Amount	 	In the event that legislative
inclusion is received on or before January 31, 2023, resulting in either (i) a permanent code (to take effect no later than
April 1, 2023) is established in respect of the TriNav Infusion System that results in a payment amount to the provider that is
equal to or higher than the current amount that providers are reimbursed by Medicare in respect of the TriNav Infusion System, then the
 “Funded Indebtedness Amount” (i.e., the Issuance Amount excluding the Greenshoe) shall equal $50,000,000 principal amount;
or (ii) the TPP in respect of the TriNav Infusion System is extended for a period of not less than one year (i.e. to at least through
December 31, 2023) and such extension results in a payment amount to the provider that is equal to or higher than the current amount
that providers are reimbursed by Medicare, then, the Funded Indebtedness Amount shall equal $25,000,000 principal amount.  Notwithstanding
the foregoing, solely in respect of clause (ii) of the immediately preceding sentence, if, following the closing but prior to December 31,
2023, a permanent code (to take effect no later than January 1, 2024) is established in respect of the TriNav Infusion System that
results in a payment amount to the provider that is equal to or higher than the current amount that providers are reimbursed by Medicare,
then, subject to the satisfaction of customary bringdown conditions, the Funded Indebtedness Amount shall be increased by $25,000,000
principal amount (i.e., the Purchaser shall fund an additional $25,000,000 principal amount of Notes beyond the $25,000,000 principal
amount of Notes initially funded by the Purchaser pursuant to clause (ii) of the immediately preceding sentence). If the payment
amount is unknown, the Purchaser may elect to delay funding until it is known or may elect to terminate this Term Sheet.

 

     

     

    

 

	Greenshoe:	 	For the two year period following
    the Closing Date, the Purchaser will have the option to purchase from, and Issuer will issue upon exercise of such option, additional
    convertible promissory notes in the aggregate principal amount up to the aggregate Funded Indebtedness Amount (“Second Tranche
    Notes”) (e.g., if the Purchaser has only become obligated to fund $25,000,000 principal amount of Notes, then the foregoing
    Greenshoe will be exercisable only for up to $25,000,000 principal amount).  The terms of the Second Tranche Notes will
    be identical to those of the initial Notes issued to Purchaser, except that (i) in a situation where the Greenshoe is exercised
    following the one-year anniversary of the Closing Date, the Second Tranche Notes will, at the option of the Purchaser, have a Maturity
    Date (which will be either the 15th day or the last day of a calendar month) that approximates as closely as possible the three-year
    anniversary of the issuance date of the Second Tranche Notes, and (ii) the Conversion Price of such Second Tranche Notes shall
    be equal to the then-applicable Conversion Price of the initial Notes issued to Purchaser and such Conversion Price shall only reset
    (if ever) to the same Conversion Price of the initial Notes issued to Purchaser when the Conversion Price of the initial Notes is
    reset as set forth below.
	 	 	 
	Denominations:	 	$1,000 per Note.
	 	 	 
	Offering Price:	 	100% of Par.
	 	 	 
	Closing Date:	 	Substantially concurrent with the closing of the Issuer’s
    business combination with TriSalus Life Sciences, Inc. (the “Target”, and such transaction, the “Business
    Combination”).  The Business Combination is expected to close in the first quarter
    of 2023.  
	 	 	 
	Ranking:	 	The Notes will be the Issuer’s senior secured
    obligations.
	 	 	 
	Maturity Date:	 	Three years from the date of
        issuance of the Notes.

	 	 	 
			
	Use of Proceeds:	 	The Issuer will use the net proceeds from its issuance
    of the Notes to pay its out-of-pocket fees and expenses related to the negotiation, documentation and consummation of the Business
    Combination.  Any remaining net proceeds will be used for working capital and general corporate purposes.

 

    - 2 -

     

    

 

	Coupon:	 	8.00% per annum, compounding semi-annually,
    paid-in-kind.
	 	 	 
	Interest Payment Dates:	 	Payable semi-annually in arrears on the two days (each
    of which will be either the 15th day or the first day of a calendar month) that approximate as closely as possible the six-month
    and one-year anniversary, respectively, of the issuance date of the Notes.
	 	 	 
	Conversion Price:	 	$10.00 per Common Share, subject to customary adjustments,
    including in respect of equity issued in connection with any equity line of credit.  The Conversion Price will also reset
    upon each of the 9-, 15- and 24-month anniversaries of the initial issuance date of the Notes to be equal to the lowest of (i) $10.00
    per Common Share, subject to customary adjustments, (ii) the trailing 10-trading day VWAP of the Common Stock and (iii) the
    then-current reset Conversion Price.
	 	 	 
	10% Conversion Blocker:	 	In the event that conversion of the Notes would cause
    any holder thereof, together with its affiliates, to beneficially own more that 9.99% of the number of Common Shares outstanding
    immediately after giving effect to such issuance, then such issuance (or the applicable portion of such issuance) shall be held in
    abeyance until such time as such issuance (or the applicable portion of such issuance) may occur without violating the 9.99% restriction
    referred to herein.
	 	 	 
	Settlement Type:	 	Common Shares.
	 	 	 
	Cash Redemption Option:	 	None.
	 	 	 
	Mandatory Conversion Option:	 	None.
	 	 	 
	Registration Rights:	 	Customary for similar transactions.
	 	 	 
	Dividends:	 	Any dividend declared by the Issuer on the Common Shares
    shall receive written consent by the Purchaser and be paid to the holders of the Notes on an as-converted basis based on the applicable
    Conversion Price at the time of the dividend.
	 	 	 
	Right of Refusal:	 	For as long as the Notes are outstanding, the Purchaser
    shall have a right of refusal to participate in any debt or equity capital raise conducted as a private placement (excluding any
    equity line of credit or any PIPE transaction that would be consummated substantially concurrent with the Closing Date) conducted
    by the Issuer in an amount sufficient for the Purchaser to maintain its implied, fully diluted equity ownership percentage in the
    Issuer (on a pro rata, as-converted basis based on the applicable Conversion Price at the time of the capital raise).
	 	 	 
	Permitted Indebtedness:	 	Other than Indebtedness reflected in the pro forma
    documentation as of signing, the terms of which must be satisfactory to Purchaser, and customary permitted indebtedness (including
    capital leases, letters of credit and cash management obligations), the Issuer may incur additional indebtedness provided (i) it
    is subordinate to the Notes and has a maturity date that is after the Maturity Date hereunder or (ii) is secured only by specific,
    newly purchased assets. All other indebtedness will require the approval of Purchaser.

 

    - 3 -

     

    

 

	Security:	 	All assets of the Issuer and its
    subsidiaries, subject to customary excluded assets and permitted liens.
	 	 	 
	Liquidity Covenant:	 	The Issuer agrees
    to maintain a balance of cash and cash equivalents of no less than $5,000,000 to be measured quarterly on March 31, June 30,
    September 30 and December 31 of each year.
	 	 	 
	Covenants:	 	Other covenants TBD
    based on diligence.
	 	 	 
	Events of Default:	 	Customary for similar transactions to include bankruptcy,
    failure to pay, etc.
	 	 	 
	PIPE	 	The Issuer shall raise an equity-based
        PIPE in support of the Business Combination from one or more purchasers without the prior written consent of the Purchaser and
        without implicating the right of first refusal set forth above, provided that such PIPE is in an aggregate amount of at least
        $15,000,000 and the shares issued in connection with the PIPE are at a price not less than $8.50 per share.

	 	 	 
	Conditions:	 	The signing of the definitive
        documentation by Purchaser is subject to customary conditions for transactions of a similar nature, including satisfactory completion
        by Purchaser of due diligence and investment committee approval.

     

    Funding of the Notes will be subject
    to (i) the satisfaction of either product reimbursement condition set forth in clause (i) or (ii) of the section entitled
    “Funded Indebtedness Amount”, (ii) entry into definitive agreements with respect to the Notes and the transactions
    in connection therewith in form and substance satisfactory to the Purchaser in its sole discretion and (iii) customary conditions
    for transactions of a similar nature, including without limitation (A) that the Business Combination will close substantially
    simultaneously, (B) all other PIPEs in support of the Business Combination will be funded in full with none of the terms thereof
    for convertible debt securities being more favorable than the terms hereof, (C) the continued listing of the Common Shares on
    a national securities exchange through the consummation of the Business Combination and the approval of the listing of the Common
    Shares underlying the Notes and (D) the Target shall not have experienced a Material Adverse Effect (as defined in the merger
    agreement for the Business Combination) that is continuing, and the Issuer shall not have experienced an Acquirer Material Adverse
    Effect (as defined in the merger agreement for the Business Combination) that is continuing. Any amendment, waiver or modification
    of the merger agreement for the Business Combination that would adversely affect the Purchaser in any material respect or that is
    otherwise intended to circumvent or frustrate the terms of the Notes transaction shall require Purchaser’s prior written consent.

 

    - 4 -

     

    

 

	Confidentiality:	 	The Issuer
                           agrees that, except as otherwise required by applicable law or if generally available to the public (including
                           following any public announcement of the Business Combination), neither it, nor its affiliates, employees
                           or representatives will disclose or allow disclosure of the existence of any discussions between the parties
                           regarding a potential transaction, this term sheet or the information contained herein to any party other
                           than its personnel and agents having a “need-to-know” and who are subject to confidentiality obligations,
                           without the express prior written approval of the Purchaser; provided that this term sheet may be disclosed
                           to the Target and its personnel, advisors and agents having a “need-to-know” who are subject to
                           confidentiality obligations and that the terms of this term sheet may be disclosed to potential PIPE investors
                           and their personnel, advisors and agents having a “need-to-know” who are subject to confidentiality
                           obligations in connection with the Business Combination. The Issuer and the Target may file a copy of this
                           term sheet with the U.S. Securities and Exchange Commission (“SEC”) in connection with any public
                           announcement of the Business Combination, subject to Purchaser’s prior consent (not to be unreasonably
                           withheld, conditioned or delayed). Notwithstanding the foregoing, the Issuer and the Target may not disclose
                           the identity of the Purchaser in any press release or description contained in a filing with the SEC without
                           the Purchaser’s prior consent.

	 	 	 
	Expenses:	 	The Issuer will reimburse the Purchaser and its affiliates
    for expenses of the Purchaser and its affiliates (including reasonable fees and expenses of attorneys, accountants, consultants,
    appraisers and out-of-pocket expenses of the Purchaser and its affiliates) incurred in connection with the transactions contemplated
    by this term sheet (including the negotiation hereof) or any similar investment or other transaction between the Purchaser and/or
    its affiliates and the Issuer, whether or not a definitive agreement for the Business Combination is signed or in respect of the
    transactions contemplated by this Term Sheet are signed, up to $300,000 in the aggregate (the “Expense Obligation”);
    provided that in the event Purchaser reasonably believes expenses of the Purchaser and its affiliates will be in excess of $300,000,
    the Purchaser will so notify the Issuer and the parties will cooperate in good faith to discuss and implement an increase of the
    Expense Obligation.  The Expense Obligation will be paid promptly (and, in any event, within 15 business days) following
    each invoice therefor.

 

    - 5 -

     

    

 

	Guaranty	 	Target
                           hereby irrevocably, absolutely and unconditionally guarantees to Purchaser,
                           as a primary obligor and not merely as a surety, the punctual and full payment of the Expense Obligation if
                           and when due and payable in accordance with and subject to the terms and conditions set forth in the section
                           entitled “Expenses”, in accordance with the terms thereof. If Issuer shall default in the due
                           and punctual performance of the Expense Obligation, Target will immediately pay or cause to be paid such Expense
                           Obligation and will immediately make full payment of any amount due with respect thereto at its sole cost
                           and expense. To the fullest extent permitted by applicable law, Target hereby expressly waives any right or
                           defense to require the Purchaser to proceed against or take any action against or pursue any remedy with respect
                           to Issuer before the Purchaser may enforce its rights hereunder against Target, and no such act or omission
                           of any kind shall in any way affect or impair this guarantee. In furtherance of the foregoing, Target acknowledges
                           that the Purchaser may, in its sole discretion, bring and prosecute a separate action or actions against Target
                           regardless of whether action is brought against the Issuer for performance of the Expense Obligation. Target
                           agrees that the Expense Obligation shall not be released or discharged, in whole or in part, or otherwise
                           affected by (i) any action or inaction on the part of Issuer (other than payment by Issuer of the Expense
                           Obligation), (ii) any change in the corporate existence, structure or ownership of the Issuer or any
                           insolvency, bankruptcy, liquidation, reorganization or other similar proceeding affecting the Issuer or its
                           assignees, (iii) the failure or delay on the part of the Purchaser to assert any claim or demand or to
                           enforce any right or remedy against Target, or (vi) the value, genuineness, validity, regularity, illegality
                           or enforceability of this Agreement or any agreement or instrument related thereto, in each case in accordance
                           with its terms. Target acknowledges that it will receive substantial direct and indirect benefits from the
                           transactions contemplated by this Agreement and that this guarantee, including specifically the waivers set
                           forth herein, are knowingly made in contemplation of such benefits.

	 	 	 
	Indemnification	 	The Issuer and Target shall
        jointly and severally indemnify and hold harmless Purchaser, its affiliates, equityholders, directors, managers, officers, employees,
        agents, advisors and representatives and any such representatives of the foregoing and each of their successors and assigns (each
        a “Purchaser Indemnified Party”) for all losses and damages of any kind or nature, liabilities, damages, costs, actions
        or causes of action, settlements, assessments, levies, fines, debts, interest, awards, judgments, penalties and expenses, including
        reasonable attorneys’ and accountants’ fees and expenses, that any Purchaser Indemnified Party may suffer, sustain
        or incur and that result from, arise out of, relate to or are caused by (i) any breach of this Term Sheet by the Issuer
        or Target or (ii) any third party claims arising out of, related to or in connection with the term sheet or the transactions
        contemplated hereby, including the Business Combination.

 

    - 6 -

     

    

 

	Waiver against Trust Account:	 	Reference is made to the final
                           prospectus of MedTech Acquisition Corporation, filed with the SEC (File No. 333-251037) on December 21, 2020, and dated as
                           of December 17, 2020 (the “Prospectus”). The Purchaser hereby acknowledges that it has read the Prospectus and
                           understands that the Issuer has established a trust account (the “Trust Account”) containing the proceeds of its initial
                           public offering (the “IPO”) and the overallotment shares acquired by its underwriters and from certain private
                           placements occurring simultaneously with the IPO (including interest accrued from time to time thereon) for the benefit of the
                           Issuer’s public stockholders (including overallotment shares acquired by the Issuer’s underwriters, the “Public
                           Stockholders”), and that, except as otherwise described in the Prospectus, the Issuer may disburse monies from the Trust
                           Account only: (a) to the Public Stockholders in the event they elect to redeem their shares in the Issuer in connection with
                           the consummation of the Issuer’s initial business combination (as such term is used in the Prospectus) (an “Initial
                           Business Combination”) or in connection with an extension of its deadline to consummate an Initial Business Combination,
                           (b) to the Public Stockholders if the Issuer fails to consummate a Business Combination within twenty-four (24) months after
                           the closing of the IPO, subject to extension by amendment to the Issuer’s organizational documents, (c) with respect to
                           interest earned on the amounts held in the Trust Account, as necessary to pay any taxes and up to $100,000 in dissolution expenses,
                           or (d) to the Issuer after or concurrently with the consummation of an Initial Business Combination. For and in consideration
                           of the Issuer entering into this term sheet and into discussions with Purchaser regarding the proposed financing described herein,
                           and for other good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Purchaser hereby
                           agrees on behalf of itself and its affiliates that, notwithstanding anything to the contrary in this term sheet, neither the
                           Purchaser nor any of its affiliates do now or shall at any time hereafter have any right, title, interest or claim of any kind in or
                           to any monies in the Trust Account or distributions therefrom, or make any claim against the Trust Account (including any
                           distributions therefrom), regardless of as a result of, in connection with or relating in any way to, this term sheet between Issuer
                           or its representatives, on the one hand, and Purchaser or its representatives, on the other hand, and regardless of whether such
                           claim arises based on contract, tort, equity or any other theory of legal liability (collectively, the “Released
                           Claims”). The Released Claims shall not include any right, title, interest or claim Purchaser may have by virtue of its
                           possible status as a Public Stockholder The Purchaser, on behalf of itself and its affiliates, hereby irrevocably waives any
                           Released Claims that the Purchaser or any of its affiliates may have against the Trust Account (including any distributions
                           therefrom) now or in the future as a result of, or arising out of, any negotiations, contracts or agreements with Issuer or its
                           representatives and agrees that it will not seek recourse against the Trust Account (including any distributions therefrom) for any
                           reason whatsoever other than any recourse it might have as a Public Stockholder (including for an alleged breach of any agreement
                           with Issuer or its affiliates). Purchaser agrees and acknowledges that such irrevocable waiver is material to this term sheet and
                           specifically relied upon by Issuer and its affiliates to induce Issuer to enter into this term sheet, and Purchaser further intends
                           and understands such waiver to be valid, binding and enforceable against Purchaser and each of its affiliates under applicable law.
                           To the extent Purchaser or any of its affiliates commences any action or proceeding based upon, in connection with, relating to or
                           arising out of any matter relating to Issuer or its representatives, which proceeding seeks, in whole or in part, monetary relief
                           against Issuer or its representatives, Purchaser hereby acknowledges and agrees that Purchaser’s and its affiliates’
                           sole monetary remedy shall be against funds held outside of the Trust Account and that such claim shall not permit Purchaser or its
                           affiliates (or any person claiming on any of their behalves or in lieu of any of them) to have any claim against the Trust Account
                           (including any distributions therefrom) or any amounts contained therein other than in any such person’s capacity as a Public
                           Stockholder.

 

    - 7 -

     

    

 

	Exclusivity:	 	In consideration of the undertaking
    by the Purchaser of the substantial time and effort incident to due diligence, structuring and documentation related to the investment
    contemplated by this Term Sheet, the Issuer hereby grants the Purchaser an exclusivity period with respect to the transaction described
    herein to complete due diligence and to negotiate and execute definitive documentation.  The exclusivity period shall begin
    on the date hereof and shall end on December 31, 2022, provided that such period shall automatically extend for an additional
    45 days in the event the Target receives a legislative inclusion reasonably likely to result in one or more conditions under the
    heading “Funded Indebtedness Amount” being satisfied.  Notwithstanding the foregoing and for greater clarity,
    neither party shall be under any obligation to negotiate definitive terms.
	 	 	 
	Termination	 	This term sheet will terminate upon the earliest to
    occur of (i) the termination of the Agreement and Plan of Merger by and among MedTech Acquisition Corporation, MTAC Merger Sub, Inc.,
    and TriSalus Life Sciences, Inc., dated as of the date hereof (the “Business Combination Agreement”) in accordance
    with its terms, (ii) the mutual written consent of the Issuer and the Purchaser, (iii) under the applicable outside date
    (pursuant to Section 11.01(b)(i) of the Business Combination Agreement as existing on the date hereof), if the Business
    Combination has not been consummated by such date, (iv) the entry into definitive agreements with respect to the Notes and (v) at
    Purchaser’s sole election, on or after January 31, 2023 (the “Termination Date”), if (a) a permanent
    code (to take effect no later than April 1, 2023) is not established in respect of the TriNav Infusion System that results in
    a payment amount to the provider that is equal to or higher than the current amount that providers are reimbursed by Medicare in
    respect of the TriNav Infusion System, or (b) the TPP in respect of the TriNav Infusion System is not extended for a period
    of not less than one year, in each case prior to the Termination Date.

 

	Governing Law:	 	This term sheet shall be governed
    by, interpreted under, and construed and enforced in accordance with the laws of the State of New York, without regard to conflicts
    of law principles.

 

    - 8 -

     

    

 

Please
acknowledge your acceptance of and agreement to the foregoing by signing and returning to the undersigned as soon as possible a counterpart
of this LOI.

 

	 	 	 	Sincerely,
	 	 	 	 	 	 
	 	 	 	MedTech Acquisition Corporation
	 	 	 	 
	 	 	 	 	 	 
	 	 	 	By:	/s/ Christopher Dewey
	 	 	 	 	Name:	Christopher Dewey
	 	 	 	 	Title:	Chief Executive Officer
	 	 	 	 	 	 
	 	 	 	 	 	 
	 	 	 	TriSalus Life Sciences, Inc.
	 	 	 	 
	 	 	 	 	 	 
	 	 	 	By:	/s/
    Sean Murphy
	 	 	 	 	Name:	Sean Murphy
	 	 	 	 	Title:	CFO
	 	 	 	 	 	 
	Accepted and agreed	 	 	 	
	 	 	 	 	 	 
	Magnetar Capital LLC	 	 	 	
	 	 	 	 	 
	 	 	 	 	 
	By:	/s/ Karl Wachter	 	 	 	
	Name:	Karl Wachter	 	 	 	
	Title:	General Counsel	 	 	 	

 

    - 9 -Document

AMENDED AND RESTATED AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENT             

             This Amended and Restated Amendment No. 1 (“Amended and Restated Amendment No. 1”) to Employment Agreement is entered into between Gregory Poilasne (“Executive”) and Nuvve Holding Corp. (the “Company”) to amend Executive’s Employment Agreement dated as of March 19, 2021 (the “Employment Agreement’). This Amended and Restated Amendment No. 1 is effective as of August 10, 2022 (the “Effective Date”), as amended and restated on November 11, 2022.

WHEREAS, the Company has employed Executive pursuant to the Employment Agreement; and 

WHEREAS, the Company and Executive have agreed that it is mutually beneficial to the Company and Executive to amend and modify certain compensation components in the Employment Agreement as provided herein.

NOW, THEREFORE, in consideration of the foregoing and the covenants in this Amendment No. 1, the parties agree as follows:

1.Section 3(a) of the Employment Agreement (and elsewhere where appropriate, except as provided herein) is amended to provide for a Base Salary rate of $65,000, which adjusted Base Salary shall apply for the period from  September 1, 2022 through August 31, 2023 (the “New Salary Period”).

1.Executive agrees that the reduction of Base Salary herein is made with Executive’s consent and does not constitute a material reduction of Executive’s Base Salary as provided for in Section 5(h)(iii) or (iv) of the Employment Agreement.

1.Notwithstanding the foregoing, for purposes of Sections 5(d) and 5(e) of the Employment Agreement, Executive’s Base Salary shall be calculated as if Executive was earning $525,000 per annum as of the date of any separation of service that would qualify Executive for severance eligibility under Sections 5(d) or 5(e).

1.In further consideration of this Amended and Restated Amendment No. 1, on August 12, 2022, the Company granted Executive a number of RSUs equal to $182,430 in shares of the Company’s common stock based on a value per share equal to the closing price of the Company’s common stock on the date of grant of the RSUs (rounded up to the nearest whole share) vesting monthly at the end of each month over the course of the New Salary Period (the “Original RSU Award”), portions of which vested on September 30, 2022 in the amount of 3,619 shares equal to a value of $5,066.60 on the vesting date based on the number of shares vesting on the vesting date multiplied by the closing price of the Company’s common stock on the vesting date (the “Vesting Date Value”) and on October 31, 2022 in the amount of 3,619 shares equal to a Vesting Date Value of $3,691.38. On November 11, 2022, the Company and Executive agree that the unvested portions of the Original RSU Award shall be cancelled, effective as of the same date, and the Company has agreed to grant Executive the replacement stock awards on the grant dates and in the amounts set forth in the table below (the “Replacement Grants”). The 

Replacement Grants shall be issued pursuant to the Company’s 2020 Equity Incentive Plan on each of the dates set forth in the table below (each, a “Grant Date”), each such grant to equal a number of shares of fully vested common stock calculated as the dollar value set forth in the table below divided by the closing price of the Company’s common stock on the applicable Grant Date (or, if the Grant Date is not a trading date, the closing price of the Company’s Common Stock on the most recent preceding trading date) (in each case rounded up to the nearest whole share), subject to Executive’s continued employment with the Company on the relevant Grant Date.
																														
	Grant Date
Nov. 30, 2022
	Grant Date
Dec. 31, 2022
	Grant Date
Jan. 31, 2023
	Grant Date
Feb. 28, 2023
	Grant Date
Mar. 31, 2023
	Grant Date
Apr. 30, 2023
	Grant Date
May 31, 2023
	Grant Date
June 30, 2023
	Grant Date
July 31, 2023
	Grant Date
Aug. 31, 2023

	$36,849.52(a)
	$15,202.50(b)
	$15,202.50
	$15,202.50
	$15,202.50
	$15,202.50
	$15,202.50
	$15,202.50
	$15,202.50
	$15,202.50

(a) Grant amount represents 1/12th of $182,430, plus a catch-up amount of $21,647.02 (representing the difference between the value of the equity compensation intended to be paid to Executive in September and October 2022 ($30,405) and the aggregate Vesting Date Value received.
(b) Grant amount represents 1/12th of $182,430.

1.This Amended and Restated Amendment No. 1 is made and effective pursuant to Section 13(e) of the Employment Agreement. All other provisions of the Employment Agreement shall remain in full force and effect. 

1.This Amended and Restated Amendment No. 1 is effective as of the date written above.

Gregory Poilasne                                                  Nuvve Holding Corp.

_____________________________                          By: _/s/ Gregory Poilasne ________________
                                                                              Name: Gregory Poilasne
                                                                              Title: Chief Executive Officer

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00350-of-00352.parquet"}]]